I can remember when Cherry attended the investors
Post# of 15624
(Total Views: 345)
Posted On: 01/21/2019 10:49:09 PM
I can remember when Cherry attended the investors conference where Ziv spoke for the company. I believe that to a large degree it was Ziv who pushed the idea that products that were tested in Phase 1 safety and passed could be marketed at least in certain markets in the world. Cherry can correct me if I'm wrong, but I believe back then it was a matter of months, not years, before some products would be marketed somewhere in the world.
When Ziv was out, it became clear that the company was going to take products beyond knowing they were safe, they wanted to see efficacy. I believe this is where we are today. If the company does a Phase 2 that clearly demonstrates efficacy in one or more products, I believe they could decide that's sufficient to bring them to market in some markets where they would be completely legal.
In some cases, such as multiple myeloma, they may wait for Phase 3 Trials and full approval before entering that market in order to gain the support of the physicians treating the disease. Don't get me wrong, I'm not certain that the product they'll be using in MM may not be something they've tried, and have on the market for other conditions, but I think they'll take it through Phase 3 in MM or other forms of cancer where they want the support of the medical community.
Something we all need to recognize is that clinical trials at Phase 3 levels will involve hundreds, and may involved thousands of patients, and they might very well be done in hundreds of clinical sites. I know that City of Hope gets involved with many trials, and I believe that such involvement is somewhat like a marketing tool if the product works as anticipated. Having over 100 clinical sites all over the world where clinicians are impressed with results certainly doesn't hurt when it comes to bringing these products once approved to the market.
I believe we'll really know that OWCP is in the big leagues when trials begin to be conducted outside of Israel, and hopefully with some sites here in the U.S. I don't know if that will happen in any Phase 2 Trials, but it certainly should if products go into Phase 3.
I do not know whether Ziv was clearly misleading investors, or if after his departure the company changed direction, but I believe it's clear the company line changed dramatically after Ziv left the company.
Gary
When Ziv was out, it became clear that the company was going to take products beyond knowing they were safe, they wanted to see efficacy. I believe this is where we are today. If the company does a Phase 2 that clearly demonstrates efficacy in one or more products, I believe they could decide that's sufficient to bring them to market in some markets where they would be completely legal.
In some cases, such as multiple myeloma, they may wait for Phase 3 Trials and full approval before entering that market in order to gain the support of the physicians treating the disease. Don't get me wrong, I'm not certain that the product they'll be using in MM may not be something they've tried, and have on the market for other conditions, but I think they'll take it through Phase 3 in MM or other forms of cancer where they want the support of the medical community.
Something we all need to recognize is that clinical trials at Phase 3 levels will involve hundreds, and may involved thousands of patients, and they might very well be done in hundreds of clinical sites. I know that City of Hope gets involved with many trials, and I believe that such involvement is somewhat like a marketing tool if the product works as anticipated. Having over 100 clinical sites all over the world where clinicians are impressed with results certainly doesn't hurt when it comes to bringing these products once approved to the market.
I believe we'll really know that OWCP is in the big leagues when trials begin to be conducted outside of Israel, and hopefully with some sites here in the U.S. I don't know if that will happen in any Phase 2 Trials, but it certainly should if products go into Phase 3.
I do not know whether Ziv was clearly misleading investors, or if after his departure the company changed direction, but I believe it's clear the company line changed dramatically after Ziv left the company.
Gary
(0)
(0)